Sunil Reddy

Clinical Trials

• Not Recruiting Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
• Recruiting A Study of CDX-1127 in Patients With Select Solid Tumor Types or Hematologic Cancers
• Not Recruiting A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma
• Recruiting Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
• Not Recruiting Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
• Recruiting Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
• Recruiting Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
• Recruiting Pilot Ipilimumab in Stage IV Melanoma Receiving Palliative Radiation Therapy
• Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
• Not Recruiting An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
• Not Recruiting Compassionate Use Trial for Unresectable Melanoma With Ipilimumab
• Not Recruiting Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
• Not Recruiting A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma
• Not Recruiting Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
• Not Recruiting Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
• Not Recruiting Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma
• Not Recruiting Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
• Not Recruiting A Study of Bevacizumab With Carboplatin and Paclitaxel Chemotherapy for the First-Line Treatment of Patients With Metastatic Melanoma
• Not Recruiting A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
• Not Recruiting A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
• Not Recruiting High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
• Not Recruiting Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma
• Not Recruiting Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
• Not Recruiting Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
• Not Recruiting Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
• Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III or Stage IV Melanoma That Has Been Removed by Surgery